These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 31765554)

  • 21. Prophylactic antiviral therapy in allogeneic hematopoietic stem cell transplantation in hepatitis B virus patients.
    Liao YP; Jiang JL; Zou WY; Xu DR; Li J
    World J Gastroenterol; 2015 Apr; 21(14):4284-92. PubMed ID: 25892880
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Overuse of prophylaxis in HBsAg and/or anti-HBc positive patients after increasing awareness to prevent reactivation in patients receiving immunosuppressive therapies: How rational are our prophylaxis decisions according to the literature?
    Yenilmez E; Cetinkaya RA
    Infez Med; 2019 Sep; 27(3):299-307. PubMed ID: 31545774
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Reactivation of hepatitis B virus in hematopoietic stem cell transplant recipients in Japan: efficacy of nucleos(t)ide analogues for prevention and treatment.
    Nakamoto S; Kanda T; Nakaseko C; Sakaida E; Ohwada C; Takeuchi M; Takeda Y; Mimura N; Iseki T; Wu S; Arai M; Imazeki F; Saito K; Shirasawa H; Yokosuka O
    Int J Mol Sci; 2014 Nov; 15(11):21455-67. PubMed ID: 25421241
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Eighteen-month lamivudine prophylaxis on preventing occult hepatitis B virus infection reactivation in patients with haematological malignancies receiving immunosuppression therapy.
    Marrone A; Capoluongo N; D'Amore C; Pisaturo M; Esposito M; Guastafierro S; Siniscalchi I; Macera M; Boemio A; Onorato L; Rinaldi L; Minichini C; Adinolfi LE; Sagnelli E; Mastrullo L; Coppola N
    J Viral Hepat; 2018 Feb; 25(2):198-204. PubMed ID: 29029365
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hepatitis B virus reactivation in patients with resolved hepatitis B virus infection receiving chemotherapy or immunosuppressive therapy.
    Su YC; Lin PC; Yu HC; Wu CC
    Eur J Gastroenterol Hepatol; 2018 Aug; 30(8):925-929. PubMed ID: 29621049
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Reactivation of chronic hepatitis B].
    Šperl J
    Vnitr Lek; 2013 Jul; 59(7):591-6. PubMed ID: 23909265
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hepatitis B surface antigen genetic elements critical for immune escape correlate with hepatitis B virus reactivation upon immunosuppression.
    Salpini R; Colagrossi L; Bellocchi MC; Surdo M; Becker C; Alteri C; Aragri M; Ricciardi A; Armenia D; Pollicita M; Di Santo F; Carioti L; Louzoun Y; Mastroianni CM; Lichtner M; Paoloni M; Esposito M; D'Amore C; Marrone A; Marignani M; Sarrecchia C; Sarmati L; Andreoni M; Angelico M; Verheyen J; Perno CF; Svicher V
    Hepatology; 2015 Mar; 61(3):823-33. PubMed ID: 25418031
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hepatitis B Virus Screening and Management for Patients With Cancer Prior to Therapy: ASCO Provisional Clinical Opinion Update.
    Hwang JP; Feld JJ; Hammond SP; Wang SH; Alston-Johnson DE; Cryer DR; Hershman DL; Loehrer AP; Sabichi AL; Symington BE; Terrault N; Wong ML; Somerfield MR; Artz AS
    J Clin Oncol; 2020 Nov; 38(31):3698-3715. PubMed ID: 32716741
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The role of anti-HBs in hepatitis B reactivation during direct-acting antiviral therapy for chronic hepatitis C.
    Spaan M; Bruce M; Agarwal K; Carey I
    Antivir Ther; 2018; 23(6):539-542. PubMed ID: 30309997
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost-effectiveness of preventing hepatitis B virus reactivation in patients with lymphoma and resolved HBV infection.
    Tsou HH; Yang HC; Hsiao CF; Hsiung CA; Liu TW; Chuang MH; Wu HY; Hsu YT; Tsui CW; Chen PJ; Cheng AL; Hsu C;
    J Formos Med Assoc; 2020 Jan; 119(1 Pt 2):335-344. PubMed ID: 31235201
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Reactivation of hepatitis B virus infection in patients with hemo-lymphoproliferative diseases, and its prevention.
    Sagnelli C; Pisaturo M; Calò F; Martini S; Sagnelli E; Coppola N
    World J Gastroenterol; 2019 Jul; 25(26):3299-3312. PubMed ID: 31341357
    [TBL] [Abstract][Full Text] [Related]  

  • 32. New Markers in Monitoring the Reactivation of Hepatitis B Virus Infection in Immunocompromised Hosts.
    Svicher V; Salpini R; Malagnino V; Piermatteo L; Alkhatib M; Cerva C; Sarmati L
    Viruses; 2019 Aug; 11(9):. PubMed ID: 31450680
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunosuppression and HBV reactivation.
    Shouval D; Shibolet O
    Semin Liver Dis; 2013 May; 33(2):167-77. PubMed ID: 23749673
    [TBL] [Abstract][Full Text] [Related]  

  • 34. HBV reactivation in patients with HCV/HBV cirrhosis on treatment with direct-acting antivirals.
    Calvaruso V; Ferraro D; Licata A; Bavetta MG; Petta S; Bronte F; Colomba G; Craxì A; Di Marco V
    J Viral Hepat; 2018 Jan; 25(1):72-79. PubMed ID: 28703895
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hepatitis B virus-specific T cell responses after stopping nucleos(t)ide analogue therapy in HBeAg-negative chronic hepatitis B.
    Rinker F; Zimmer CL; Höner Zu Siederdissen C; Manns MP; Kraft ARM; Wedemeyer H; Björkström NK; Cornberg M
    J Hepatol; 2018 Sep; 69(3):584-593. PubMed ID: 29758333
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparative effectiveness of nucleos(t)ide analogues in chronic hepatitis B patients undergoing cytotoxic chemotherapy.
    Tseng CM; Chen TB; Hsu YC; Chang CY; Lin JT; Mo LR
    Asia Pac J Clin Oncol; 2016 Dec; 12(4):421-429. PubMed ID: 27435683
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Serum Level of Antibodies Against Hepatitis B Core Protein Is Associated With Clinical Relapse After Discontinuation of Nucleos(t)ide Analogue Therapy.
    Chi H; Li Z; Hansen BE; Yu T; Zhang X; Sun J; Hou J; Janssen HLA; Peng J
    Clin Gastroenterol Hepatol; 2019 Jan; 17(1):182-191.e1. PubMed ID: 29902645
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Randomized controlled trial of entecavir prophylaxis for rituximab-associated hepatitis B virus reactivation in patients with lymphoma and resolved hepatitis B.
    Huang YH; Hsiao LT; Hong YC; Chiou TJ; Yu YB; Gau JP; Liu CY; Yang MH; Tzeng CH; Lee PC; Lin HC; Lee SD
    J Clin Oncol; 2013 Aug; 31(22):2765-72. PubMed ID: 23775967
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hepatitis B reactivation in occult viral carriers undergoing hematopoietic stem cell transplantation: A prospective study.
    Seto WK; Chan TS; Hwang YY; Wong DK; Fung J; Liu KS; Gill H; Lam YF; Lau EHY; Cheung KS; Lie AKW; Lai CL; Kwong YL; Yuen MF
    Hepatology; 2017 May; 65(5):1451-1461. PubMed ID: 28027590
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hepatitis B virus reactivation and efficacy of prophylaxis with lamivudine in patients undergoing allogeneic stem cell transplantation.
    Giaccone L; Festuccia M; Marengo A; Resta I; Sorasio R; Pittaluga F; Fiore F; Boccadoro M; Rizzetto M; Bruno B; Marzano A
    Biol Blood Marrow Transplant; 2010 Jun; 16(6):809-17. PubMed ID: 20060484
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.